INNOVENT BIO (01801): TYVYT® (Ipilimumab N01 Injection) Approved by NMPA for Combined Use with Sintilimab in Neoadjuvant Treatment of Colon Cancer

Stock News2025-12-29

INNOVENT BIO (01801) announced that TYVYT® (Ipilimumab N01 Injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, R&D code: IBI310) has received approval for marketing from China's National Medical Products Administration (NMPA). The approval is for its use in combination with sintilimab as a neoadjuvant treatment for patients with operable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. TYVYT® (Ipilimumab N01 Injection) is the first domestically developed anti-CTLA-4 monoclonal antibody approved in China and the first anti-CTLA-4 therapy globally approved for the neoadjuvant treatment of colon cancer. This short-term neoadjuvant regimen, used in combination with sintilimab, can significantly increase the pathological complete response rate, benefiting patients with MSI-H/dMMR colon cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173862941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173862941","market":"us","top_or_hot":-1,"title":"INNOVENT BIO (01801): TYVYT® (Ipilimumab N01 Injection) Approved by NMPA for Combined Use with Sintilimab in Neoadjuvant Treatment of Colon Cancer","media":"Stock News","content":"<p>INNOVENT BIO (01801) announced that TYVYT® (Ipilimumab N01 Injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, R&D code: IBI310) has received approval for marketing from China's National Medical Products Administration (NMPA). The approval is for its use in combination with sintilimab as a neoadjuvant treatment for patients with operable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. TYVYT® (Ipilimumab N01 Injection) is the first domestically developed anti-CTLA-4 monoclonal antibody approved in China and the first anti-CTLA-4 therapy globally approved for the neoadjuvant treatment of colon cancer. This short-term neoadjuvant regimen, used in combination with sintilimab, can significantly increase the pathological complete response rate, benefiting patients with MSI-H/dMMR colon cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOVENT BIO (01801): TYVYT® (Ipilimumab N01 Injection) Approved by NMPA for Combined Use with Sintilimab in Neoadjuvant Treatment of Colon Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOVENT BIO (01801): TYVYT® (Ipilimumab N01 Injection) Approved by NMPA for Combined Use with Sintilimab in Neoadjuvant Treatment of Colon Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-29 07:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOVENT BIO (01801) announced that TYVYT® (Ipilimumab N01 Injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, R&D code: IBI310) has received approval for marketing from China's National Medical Products Administration (NMPA). The approval is for its use in combination with sintilimab as a neoadjuvant treatment for patients with operable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. TYVYT® (Ipilimumab N01 Injection) is the first domestically developed anti-CTLA-4 monoclonal antibody approved in China and the first anti-CTLA-4 therapy globally approved for the neoadjuvant treatment of colon cancer. This short-term neoadjuvant regimen, used in combination with sintilimab, can significantly increase the pathological complete response rate, benefiting patients with MSI-H/dMMR colon cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"","article_id":"1173862941","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173862941","pubTimestamp":1766965218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOVENT BIO (01801) announced that TYVYT® (Ipilimumab N01 Injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, R&D code: IBI310) has received approval for marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1583":"高瓴概念","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","01801":"信达生物","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1161":"生物科技","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC"},"translate_title":"信达生物(01801)：达伯舒®（伊匹单抗N01注射液）获NMPA批准联合信迪利单抗用于结肠癌新辅助治疗","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"INNOVENT BIO (01801) announced that TYVYT® (Ipilimumab N01 Injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, R&D code: IBI310) has received approval for marketing from China's National Medical Products Administration (NMPA). The approval is for its use in combination with sintilimab as a neoadjuvant treatment for patients with operable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. TYVYT® (Ipilimumab N01 Injection) is the first domestically developed anti-CTLA-4 monoclonal antibody approved in China and the first anti-CTLA-4 therapy globally approved for the neoadjuvant treatment of colon cancer. This short-term neoadjuvant regimen, used in combination with sintilimab, can significantly increase the pathological complete response rate, benefiting patients with MSI-H/dMMR colon cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173862941","isCrawlerRequest":true}